🇺🇸 FDA
Patent

US 10562882

Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions

granted A61PA61P1/04A61P25/04

Quick answer

US patent 10562882 (Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions) held by Takeda Pharmaceutical Company Limited expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P1/04, A61P25/04, A61P25/18, A61P25/28